AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
WASHINGTON -- The synthetic retinoid fenretinide (4-HPR), an analogue of vitamin A, may hold promise as a chemoprevention agent for ovarian cancer patients, Mary Daly, M.D., said at the annual meeting of the Ovarian Cancer National Alliance.
"This drug has many, many positive effects that have been touted. Some may have been over-touted. It is known to be an important agent in cell differentiation and inhibiting growth factors," said Dr. Daly of Fox Chase Cancer Center, Philadelphia.
She referred to a small study done by researchers at the Cancer Family Clinic of the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan (Gynecol Oncol. 2002;86:24-7). Investigators conducted a 5-year randomized clinical trial on the effect of fenretinide on the prevention of second breast cancer.
"They found no effect on breast cancer but they found a marked effect on decreasing rates of ovarian cancer," she said.
Dr. Daly and her colleagues hypothesize that the ...
Source: HighBeam Research, Study to look at drug to prevent ovarian cancer.(Gynecology)